BioLife

Financials
2022 Fiscal Year Annual Revenue
$30.17 Billion
2022 Fiscal Year Gross Profit
$20.79 Billion
2022 Fiscal Year Annual Net Income
$3.55 Billion
2022 Fiscal Year Gross Profit Growth
2.67%
2022 Number of U.S. Stores
180
Credit Rating
Leases are guaranteed by Takeda Pharmaceuticals U.S.A., Inc, which is a wholly-owned subsidiary of Takeda Pharmaceutical Co. Ltd., which is S&P Rated: Investment Grade BBB+ (Long-Term) A-2 (Short-Term)